In patients with immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long-term use (eg, corticosteroids) and overuse of off-label therapies (eg, rituximab) while approved, more efficacious options exist. These approaches may not only fail to address symptoms and burden of disease, but may also worsen health-related quality of life. A better understanding of available second-line treatments may ensure best use of therapeutic options and thereby optimize patient outcomes.
| I N TR ODU C TI ON
Immune thrombocytopenia (ITP) is characterized by a reduction in platelet count that may be associated with severe bleeding in some patients. 1 The disease may have a substantial impact on the patient's quality of life, resulting, at least in part, from significant treatment burden. Indeed, health-related quality of life for patients with ITP may be worse than that of patients with many other chronic conditions, including hypertension and arthritis. immunoglobulin. 3 These therapies are used as upfront treatment in newly diagnosed patients and also as rescue therapies in patients with established ITP, with the goal of rapidly elevating platelet counts and preventing or controlling bleeding events. 4 While corticosteroids and immunoglobulins produce an initial response in most patients (60%-70% and 90%, respectively), the response is usually transient (<6 months and 2-4 weeks, respectively) and the medications must be readministered if the patient's platelet count does not stabilize. 5 Repeated or prolonged administration of first-line therapies is typically not suitable due to significant adverse effects (eg, osteoporosis, diabetes, cataracts, weight gain, infections) with corticosteroids and high cost, inconvenience of frequent infusions, and debilitating postinfusion headache with immunoglobulins. 4, 6, 7 Spontaneous remissions in patients who have never received treatment are uncommon in adults with ITP (9%). In many patients, the disease becomes persistent (3-12 months duration) or chronic (>12 months duration), and second-line treatment may be needed.
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| S EC O ND -LI N E TRE A TM E NT OP TI O NS
Second-line or maintenance therapy in persistent or chronic ITP (hereafter referred to as ITP) aims to establish a durable platelet response and to minimize bleeding events with a treatment that is safe, tolerable, and convenient for long-term management. Splenectomy, thrombopoietin receptor agonists (TPO-RAs), and rituximab are the standard secondline treatment options in current use. 3, 4 Before initiation of a secondline therapy, it is advisable to confirm the diagnosis of primary ITP by excluding potential non-immune causes of thrombocytopenia as well as causes of secondary ITP if these have not been previously ruled out.
| Splenectomy
Conventionally, splenectomy has been the principal option for longterm management of ITP because of its potential to induce long-term remission. Splenectomy provides a high initial response rate (85%);
however, up to 30% of responders will relapse during the 10 years fol- and there is no widely available and reliable means of predicting whether an individual patient will respond. 10 In addition, splenectomy is associated with serious short-and long-term risks. Surgical complications were reported in 10% of patients in the 30-day period following splenectomy, even when less-invasive laparoscopic methods were used. 10 Furthermore, lack of splenic function may result in infections, thromboembolism, and possibly an increased incidence of malignancy, which result in an increased risk of death that persists for >10 years after surgery. 11 Based on a study of 8149 US veterans who had splenectomy for any indication, the risk of death due to certain events was 3-to 4-fold higher in patients who had undergone splenectomy versus those with intact spleens (the risks of septicemia, pulmonary embolism, and non-Hodgkin lymphoma were 3.02-, 4.53-, and 4.69-fold higher, respectively). 11 In addition, another study in 9976 patients with ITP revealed a 2.7-fold increased risk of venous thromboembolism and a 1.6-to 3.1-fold increased risk of sepsis (depending on timing and comorbidities) 90 days after splenectomy (median follow-up of 120 months), but an increase in the risk of malignancy was not reported. 12 Thus, splenectomized patients need lifelong management to prevent sepsis, such as vaccinations and prophylactic antibiotics, as well as surveillance for relapse. The advent of pharmaceutical second-line treatment options has significantly decreased the use of splenectomy in ITP. 13, 14 However, splenectomy may still be preferred by some patients who desire independence from medications. 15 
| Thrombopoietin receptor agonists
Thrombopoietin receptor agonists are approved for the treatment of patients with chronic ITP who had an insufficient response to either a first-line therapy or splenectomy. 16, 17 Thrombopoietin receptor agonists were developed after the US clinical trials of recombinant human thrombopoietin (rhTPO) were withdrawn because injection of a pegylated, truncated, and nonglycosylated fragment of TPO (pegylated recombinant human megakaryocyte growth and development factor) caused anti-thrombopoietin antibody development that resulted in severe thrombocytopenia. 18 While the same theoretical risk exists with full-length recombinant TPO, this treatment is still being used in China and there are no published cases of neutralizing anti-TPO antibody development with this agent. 19, 20 TPO-RAs share no structural analogy with endogenous TPO and thus are not expected to induce formation of anti-TPO antibodies. 21 Moreover, they have improved pharmacological properties compared with rhTPO including more potent activation of the TPO receptor and convenience of administration. [16] [17] [18] 22 In Western countries, TPO-RAs are the only widely available drug class that directly and specifically improves platelet counts by increasing platelet production in the bone marrow. 23 There Thrombopoietin receptor agonists are conventionally considered to be lifelong therapies that need to be used continuously to maintain response. However, accumulating data suggest that some patients who use TPO-RAs may achieve long-term remissions that are sustained off treatment. Although randomized, placebo-controlled, long-term studies that would directly demonstrate the remission-inducing potential of TPO-RAs are not available, it appears unlikely that remissions observed in the TPO-RA discontinuation studies are purely spontaneous. Earlier studies showed that the rate of spontaneous remissions in adult patients is only about 9%, 9 while the overall rate of long-term (6 months) remission in TPO-RA studies is nearly 30%. [34] [35] [36] [37] Second, spontaneous remissions are less frequent following the first year after diagnosis, but most patients who achieved remission in TPO-RA studies had ITP for >1 year, and some had been living with ITP for much longer (up to 54 years). 1, 34, [36] [37] [38] [39] The authors speculated that this putative disease-modifying activity of TPO-RAs could be linked to the TPO-RAmediated restoration of impaired regulatory T-cell function and immune tolerance that was observed in patients with ITP. 37, 39, 40 The most common adverse events (5% and greater than placebo) in clinical trials in adult patients with ITP were nausea, diarrhea, upper respiratory tract infection, vomiting, increased alanine aminotransferase, myalgia, and urinary tract infection with eltrombopag 16 ; and arthralgia, dizziness, insomnia, myalgia, pain in extremity, abdominal pain, shoulder pain, dyspepsia, and paresthesia with romiplostim. 17 Potential risks of TPO-RAs include rebound thrombocytopenia after discontinuation, thromboembolic events, and bone marrow reticulin formation. 4, 16, 17 Although an increased risk of thromboembolic events was not confirmed in placebo-controlled trials of TPO-RAs, 25, 41 it is prudent to be cautious, especially in patients with preexisting thrombotic risk factors. Similarly, because of its association with hepatobiliary laboratory abnormalities and hepatotoxicity, it is advisable to use eltrombopag with caution in patients with liver disease with close monitoring of liver function tests. Bone marrow reticulin formation, which is more common in patients with ITP than in hematologically normal patients at baseline, occurred in studies with TPO-RAs. 42 However, these events were typically mild, asymptomatic, and reversible upon treatment interruption. 42, 43 In toxicology studies of rodents exposed to suprapharmacologic concentrations of eltrombopag, cataract events were noted in juvenile animals. 16 In the eltrombopag extension study, however, the rate of cataract formation was not greater than the expected rate in the general adult population. 44 Preliminary data in patients with myelodysplastic syndromes suggested a potential risk of progression to leukemia with TPO-RAs. 16, 17, 45, 46 Neutralizing antibodies against romiplostim have been detected in patients receiving romiplostim in clinical trials; however no neutralizing activity against endogenous TPO has been observed. 17 Until platelet counts are stabilized, they should be monitored weekly in all patients receiving TPO-RAs. For patients receiving CUKER eltrombopag, a baseline liver enzyme test and ocular examination with regular follow-up monitoring is recommended. 16 In addition, peripheral blood smears may be periodically reviewed to monitor for changes that could potentially indicate bone marrow reticulin formation.
| Anti-CD20 antibody
The anti-CD20 antibody rituximab is used in patients with refractory ITP primarily based on experience in other autoimmune diseases, as well as uncontrolled studies in ITP. It is licensed for use in certain hematological malignancies and rheumatoid arthritis, but not in ITP. 47 The optimal dosing of rituximab for ITP has not been defined. It is typically administered at a dose of 375 mg/m 2 over 4 consecutive weekly infusions, although lower doses may be sufficient. 48, 49 Based on a meta-analysis of randomized controlled trials, the complete response rate to a single course of rituximab by 6 months is 47% versus 32.5% with standard of care, however, no statistically significant difference was found in overall response rate (P 5 .11) and reduction in bleeding events (P 5 .44). 50 Long-term studies of rituximab have also shown disappointing results. A placebo-controlled long-term study found no significant benefit of rituximab beyond 1.5 years compared with placebo (P 5 .65). 51 In a retrospective analysis of adults with an initial response to rituximab, the response rate at 5 years was only 21%. 52 However, for certain patient populations and in combination with corticosteroids, rituximab may provide durable remissions. 53, 54 Most recently, a small study in 49 patients found that among adult females with newly diagnosed or persistent ITP (disease duration of <1 year) who had shown an initial response to rituximab and high-dose dexamethasone, a remarkable percentage of patients (79%) achieved a durable remission (>48 months), whereas remission rates in other populations were dramatically lower (0%-21%). 54 Although these results require confirmation, they suggest that response rates to rituximab are influenced by gender and disease duration.
Rituximab is usually well tolerated in patients with ITP, but infusion reactions (rash, urticaria, fever, myalgia, headache, and transient hypertension) are relatively common (20%). 55 Particularly among patients who receive multiple courses of rituximab, there is a risk of hypogammaglobulinemia, and monitoring serum immunoglobulin levels before and periodically after rituximab may be needed. 56, 57 Rituximab has also been associated with rare but potentially fatal complications, including severe mucocutaneous reactions, reactivation of hepatitis B, and multifocal leukoencelopathy. 10, 47 In addition, a meta-analysis of the safety population in the uncontrolled rituximab trials in ITP revealed a relatively high death rate (3%), but it was not clear if reported deaths were attributable to rituximab. 58 
| Other treatments
Other agents, including mycophenolate mofetil, azathioprine, danazol, dapsone, vinca alkaloids, sirolimus, cyclosporine, and cyclophosphamide have been used in ITP as alternative treatments since they are less expensive compared with rituximab and the TPO-RAs. 4, 59 However, unlike standard second-line treatments, these agents have not been subject to randomized-controlled trials to establish their safety and efficacy in ITP. In addition, limited clinical data on their safety and efficacy suggest that they have lower response rates and greater toxicity compared with approved treatments. Thus, current guidelines recommend that they be reserved for patients who do not respond to or cannot tolerate standard second-line therapies. 3, 4 These agents may play an important role in the second-line treatment of ITP in countries where access to standard second-line therapies is limited.
| CH A LL EN GE S I N TH E T RA N SIT I ON T O S EC OND -LI N E TRE A TM EN T
In patients who require additional treatment after first-line therapy, there is no consensus on when to stop first-line treatment and switch to a therapy more suitable for maintaining a long-term response. In addition, there is no consensus on which second-line option to try first.
Perhaps because of this uncertainty, several common suboptimal treatment approaches have emerged in clinical practice.
| Excessive duration of corticosteroid treatment
As corticosteroid treatment is a familiar, low-cost, and efficacious option for many patients, some clinicians maintain their patients on corticosteroids for months or even years before transitioning to a second-line therapy. This practice may increase not only the risk of bleeding due to poor management of thrombocytopenia as the corticosteroid dose is tapered, but also the risk of adverse events associated with prolonged exposure to corticosteroids, such as weight gain, diabetes, osteoporosis, cataracts, and infections. 
| Premature splenectomy
Splenectomy may induce remission and eliminate the need for further treatment, and thus it is sometimes considered soon after diagnosis and before the exhaustion of other treatment options. However, splenectomy is an invasive and irreversible process that leads to a loss of multiple hematological and immunological functions. 10 Therefore, unless there is an urgent need to raise the platelet count and the patient does not respond to or cannot tolerate second-line medical therapies, splenectomy should generally be reserved for patients in whom remission is unlikely (ie, those with a disease duration of >1 year). As discussed, efficacy of rituximab also appears to be affected by age, sex, and duration of ITP. In male patients and patients who have had ITP for >1 year, rituximab may have reduced efficacy. 54 Considering potential risks associated with rituximab, a variable and unpredictable time to response (1-8 weeks 3, 5 ), and limited long-term benefits in most patients, indiscriminate use of rituximab should be avoided.
| Use of other off-label agents
The agents listed above as "other treatments" have been utilized in ITP as alternative treatments due to cost and availability considerations.
However, these agents may produce highly variable responses in individual patients and may require weeks or months to be effective. 
| BE S T P R AC TI CE S 4.1 | Transitioning to second-line therapy
My approach to selecting patients for second-line therapy is depicted in Figure 1 . If a first-line therapy has produced a response that lasted for >6 months and was tolerable, the patient could be re-treated with it. However, I generally discontinue first-line therapy and switch to second-line therapy if any of the following criteria are met: (1) the patient cannot tolerate first-line treatment; (2) the patient does not respond to first-line treatment within 2-4 weeks; (3) the patient's response to the last course of therapy is lost within 6 months, including a failure to taper corticosteroids to a low dose (ie, prednisone 5 mg/ day) due to loss of response. In addition to these criteria, patient preferences and treatment burden should also be incorporated in decision making.
| Selection of second-line therapy and beyond
The risks and benefits of all second-line management options should be discussed with the patient before making a treatment decision. My approach to selecting optimal second and subsequent lines of treatment for patients with ITP is shown in Figure 2 . Finally, the perception that use of TPO-RAs constitutes a lifelong commitment for continuous treatment can be offset by the knowledge that as many as 30% of patients with ITP using TPO-RAs may achieve longterm remission off therapy.
Patients with ITP experience a high burden of disease, and it is important to offer management options that will improve quality of life. When possible, treatment options that are compatible with the personal preferences and lifestyle of the patient should be offered.
Oral treatments taken once a day may be preferred by some patients, but others may favor injections that are administered less frequently.
For patients who want to minimize their medication and monitoring needs, splenectomy may be the most desirable option.
An in-depth understanding of second-line treatment options will help optimize management of ITP and patient outcomes by ensuring the best use of available therapeutic options.
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